webcast resource

Quality management in the collection and management of biospecimens for clinical trials biobanking and why this impact health care

QA & QC from pre analytical steps to clinical utility

September 08, 2016 | Length: 18:10 min


Congress:Innovation and Biomarkers in Cancer Drug Development
Presenter:H. Juhl

Founder and CEO of Indivumed GmbH and IndivuTest GmbH in Hamburg. Hartmut Juhl attended the Medical School at Hamburg University, Germany and worked for 12 years as an academic surgeon in oncology and cancer research at the University Clinic Hamburg-Eppendorf and, later, Christian-AlbrechtsUniversity in Kiel, Germany. In 1998 he became Associate Professor for Oncology and Surgery at Georgetown University, Washington, DC (USA). In 2002, he founded Indivumed GmbH in Hamburg, a company specialized on highly standardized tumor biobanking, clinical data collection and research service. In 2008, he founded together with Indivumed GmbH and scientists from Johns Hopkins University, Inostics GmbH to commercialize a new technology that allows plasma-based mutation analysis of circulating free tumor DNA (“liquid biopsy”). After 4 years the company was sold to Sysmex Corporation. He is CEO of the Indivumed Group including IndivuTest GmbH, a clinical diagnostic laboratory founded in 2011, offering patients innovative diagnostic for individualizing cancer therapy. He holds an extraordinary professorship at theMedical Faculty of Hamburg University and is Adjunct Professor at the Lombardi Cancer Center of Georgetown University in Washington, D.C.

Category: Cancer;